Skip to main content

Peer Review reports

From: Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Original Submission
10 Dec 2021 Submitted Original manuscript
11 Mar 2022 Reviewed Reviewer Report - Hicham Ibrahim Cheikh Hassan
1 May 2022 Reviewed Reviewer Report - Tarek Abdelaziz
30 Jun 2022 Author responded Author comments - Peter W. Nickerson
Resubmission - Version 2
30 Jun 2022 Submitted Manuscript version 2
1 Aug 2022 Reviewed Reviewer Report - Alexander Gough
28 Sep 2022 Author responded Author comments - Peter W. Nickerson
Resubmission - Version 3
28 Sep 2022 Submitted Manuscript version 3
6 Oct 2022 Reviewed Reviewer Report - Alexander Gough
7 Nov 2022 Author responded Author comments - Peter W. Nickerson
Resubmission - Version 4
7 Nov 2022 Submitted Manuscript version 4
Publishing
8 Nov 2022 Editorially accepted
22 Dec 2022 Article published 10.1186/s13063-022-06897-3

You can find further information about peer review here.

Back to article page